Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Bridgebio Pharma, Inc. (BBIO)
A forensic read on Bridgebio Pharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-7.7
Distress distance
Watch
Earnings quality
5
Forensic signals
-22.2
P / E (ttm)
$16.7B
Market cap
0.00%
Dividend yield
126.3%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bridgebio Pharma, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -7.7, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-530.6%
FY2025
Return on invested capital.Return on invested capital is -530.6% in the latest fiscal year and slipping from -324% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+9.1%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +30% over the last 3 years to FY2025 (+9.1%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~9.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~23%.
FCF ($447M)
FY2025
Shareholder returns.Returned $48M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($447M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
52d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 5 to 52 days FY2024→FY2025 (receivables +2853% vs revenue +126%). Deferred revenue grew +13475% over the same period, which accounts for part of the balance but not for a day count that widened against the same quarters a year earlier. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 3 consecutive quarters (Dec 2025 +9, Mar 2026 +6, Jun 2026 +32 days). In the latest of them the receivable balance grew +231% against sales +120%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid.
Key fundamentals
Latest Revenue$502.1M
Revenue Growth YoY+126.3%
Revenue CAGR (3yr)+86.3%
Net Margin-144.4%
Free Cash Flow-$447.0M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bridgebio Pharma, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
Bridgebio Pharma, Inc. (BBIO) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
26% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 26% of revenue in FY2025 — about $0.69 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 9.2% a year and is falling.